Pfizer CapEx decreased by 48.4% to $436.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 22.7%, from $564.00M to $436.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows relatively stable performance with a -0.8% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $537.00M | $618.00M | $1.00B | $643.00M | $751.00M | $841.00M | $1.00B | $1.14B | $914.00M | $810.00M | $1.04B | $704.00M | $637.00M | $651.00M | $917.00M | $564.00M | $618.00M | $602.00M | $845.00M | $436.00M |
| QoQ Change | — | +15.1% | +62.1% | -35.8% | +16.8% | +12.0% | +19.0% | +13.8% | -19.8% | -11.4% | +28.9% | -32.6% | -9.5% | +2.2% | +40.9% | -38.5% | +9.6% | -2.6% | +40.4% | -48.4% |
| YoY Change | — | — | — | — | +39.9% | +36.1% | -0.1% | +77.1% | +21.7% | -3.7% | +4.3% | -38.2% | -30.3% | -19.6% | -12.2% | -19.9% | -3.0% | -7.5% | -7.9% | -22.7% |